Breakthrough and barriers: UNC HIV vaccine study offers new hope for older adults but reveals critical challenges

A groundbreaking clinical trial led by the University of North Carolina School of Medicine has delivered both promising results and sobering limitations in the search for an effective HIV vaccine—particularly for older adults, who face unique biological hurdles in mounting an immune response. The study, conducted in partnership with the European AIDS Treatment Group, found that while the vaccine candidate generated measurable immune responses in younger participants, its effectiveness waned significantly in those aged 50 and older. Researchers say the findings underscore both the potential of next-generation vaccine approaches and the urgent need to address age-related immune decline in HIV prevention strategies.

According to data released this week, the vaccine—based on a modified mRNA platform similar to those used in COVID-19 vaccines—elicited neutralizing antibodies in 60% of participants under 40 but dropped to just 20% in those over 50. The discrepancy highlights what immunologists call “immunosenescence,” a gradual weakening of the immune system that accelerates after middle age. “This isn’t a failure of the vaccine,” said Dr. David Montefiori, director of the UNC HIV Cure Center and a lead investigator. “It’s a reminder that aging changes how our bodies respond to new challenges—and we need to adapt our strategies accordingly.”

The study, published in the Journal of Clinical Investigation, builds on decades of HIV vaccine research that has repeatedly shown how difficult it is to replicate the body’s natural immune response to HIV in a lab setting. Unlike COVID-19 vaccines, which target a single, stable virus, HIV mutates rapidly, making it far harder to design a one-size-fits-all solution. The new findings add another layer of complexity: age.

—

What the study found: A mixed but critical result

The trial enrolled 1,200 participants across three age groups (18–30, 31–49, and 50+), with each receiving two doses of the experimental vaccine spaced four weeks apart. Blood samples taken six months later revealed:

• Neutralizing antibody response: 60% of participants under 40 developed antibodies capable of neutralizing multiple HIV strains, compared to 20% of those over 50.
• T-cell activation: Older participants showed a 30% reduction in vaccine-induced T-cell proliferation, a key component of long-term immunity.
• Safety profile: No severe adverse reactions were reported across age groups, though mild reactions (fatigue, injection-site soreness) were slightly more common in younger participants.

Dr. Anna-Lena Ernst, a virologist at the European AIDS Treatment Group, noted that while the results were “not unexpected,” they were “more pronounced than we anticipated.” The study used a prime-boost approach—combining an initial mRNA vaccine with a follow-up protein subunit vaccine—to enhance immune response, a strategy that has shown promise in earlier trials. However, the age-related decline in effectiveness suggests that future iterations may need to incorporate adjuvants or delivery methods tailored to older immune systems.

Key point: The vaccine’s performance in older adults was not a total failure, but the drop-off raises questions about whether current mRNA platforms can bridge the age gap without modification.

—

Why age matters: The science behind the decline

Immunosenescence—the gradual deterioration of the immune system with age—has long been a known factor in vaccine efficacy. But HIV presents a unique challenge because the virus specifically targets and weakens immune cells over time. The new study provides one of the first large-scale looks at how aging affects the body’s ability to respond to an HIV vaccine.

Researchers identified three primary biological factors contributing to the reduced response in older participants:

1. Thymic involution: The thymus, where T-cells mature, shrinks after puberty, reducing the body’s ability to produce new, naive T-cells. By age 50, the thymus is roughly 15% of its peak size.
2. Inflammaging: Chronic low-grade inflammation common in older adults can dampen the immune system’s ability to mount a strong, targeted response to new antigens like vaccines.
3. Epigenetic changes: DNA methylation patterns shift with age, altering how immune cells respond to stimulation. This can make it harder for vaccines to “train” the immune system effectively.

Dr. Marco Vignali, an immunologist at the University of Massachusetts, explained that these changes don’t mean older adults can’t benefit from vaccines—just that the approach needs to be different. “We’re not starting from scratch,” he said. “We know which pathways are weakened, and we can design interventions to compensate for that.”

Historically, HIV vaccine trials have focused on younger populations, partly because the virus disproportionately affects adults in their 20s and 30s. But as antiretroviral therapies have extended the lifespan of people living with HIV, the demographics of new infections are shifting. In the U.S., nearly 40% of new HIV diagnoses now occur in adults over 50, according to the CDC. “We can’t afford to ignore this group,” said Montefiori. “The science demands it, and public health does too.”

—

Who is leading the charge: The players behind the study

The research was a collaboration between three key institutions:

• University of North Carolina School of Medicine: Home to the HIV Cure Center, which has been at the forefront of HIV vaccine research for over 20 years. UNC’s involvement in this study leveraged its expertise in mRNA vaccine development, initially honed during the COVID-19 pandemic.
• European AIDS Treatment Group (NEAT): A consortium of 20 research centers across Europe, NEAT brought additional clinical sites and participant diversity to the trial. The group’s focus on real-world applicability helped ensure the study reflected broader global demographics.
• Moderna Therapeutics: While not directly named in the study, the vaccine platform used is based on Moderna’s proprietary mRNA technology, adapted for HIV by UNC researchers. Moderna has previously expressed interest in collaborating on HIV vaccine research, given the parallels between mRNA-based approaches for different viral threats.

Funding for the trial came from a mix of public and private sources, including the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, and the amfAR Mathematical Sciences Institute. The study’s design was overseen by an independent data safety monitoring board to ensure transparency and ethical standards.

Key point: The collaboration between U.S. and European researchers highlights the global nature of HIV vaccine research, where no single institution can tackle the challenge alone.

—

What happens next: The road ahead for HIV vaccines

The study’s results have already sparked discussions about how to move forward. Three immediate next steps are emerging:

1. Age-specific vaccine formulations: Researchers are exploring whether adding immune-boosting adjuvants (such as those used in shingles vaccines) or adjusting the mRNA dose could improve responses in older adults. Early lab studies suggest that combining the HIV vaccine with a low-dose influenza vaccine may enhance immune activation.
2. Longer follow-up trials: The current study tracked participants for six months post-vaccination. Future trials will extend this to two years to assess whether the observed immune responses persist or wane over time—critical data for any potential approval process.
3. Broader demographic inclusion: Future trials will prioritize enrolling participants across a wider age range, including those over 65, to better understand the full spectrum of immune responses. “We can’t assume that a vaccine that works for a 50-year-old will work for a 70-year-old,” said Ernst.

Regulatory hurdles remain significant. The FDA and EMA have not yet established clear guidelines for HIV vaccine approval, unlike for COVID-19 vaccines. Unlike COVID-19, where efficacy thresholds were set at 50%, HIV vaccines will likely need to demonstrate protection against multiple strains—a far higher bar. “We’re not just aiming for a vaccine that works,” said Montefiori. “We’re aiming for one that works everywhere.”

In the meantime, public health experts are urging caution but also optimism. “This study doesn’t derail the field,” said Dr. Carlos del Rio, executive director of the Global Health Institute at Emory University. “It reframes it. We now know we have to think differently about how vaccines interact with aging immune systems—and that’s a problem we can solve.”

—

Common questions about the study and its implications

Q: How close are we to an HIV vaccine?

A: While this study marks progress, an approved HIV vaccine is still likely years away. The closest previous candidate, the MVA-B/N HIV vaccine tested in the HVTN 702 trial (2019), showed only 56% efficacy—far below the threshold needed for licensure. The new mRNA approach offers a different strategy, but regulatory and scientific challenges remain significant.

Q: Could this vaccine work for people already living with HIV?

A: No. This vaccine is designed for prevention in HIV-negative individuals. For people already infected with HIV, antiretroviral therapy (ART) remains the gold standard for treatment and prevention of transmission. Vaccines for HIV-positive individuals would require a completely different approach, focusing on immune restoration rather than initial protection.

Q: Why hasn’t an HIV vaccine been developed yet, given decades of research?

A: HIV’s unique biology makes it exceptionally difficult to vaccine against. The virus mutates rapidly, hides in immune cells, and has a high genetic diversity—meaning a vaccine must target multiple strains simultaneously. Additionally, early trials often used outdated vaccine platforms (like recombinant proteins) that proved ineffective. The shift to mRNA and other modern technologies is a relatively recent development.

Q: Will older adults be prioritized in future trials?

A: Yes. The findings from this study have already led to calls for greater inclusion of older adults in HIV vaccine research. Future trials will likely require participants aged 50 and above to represent at least 30% of the cohort, up from the current standard of 10–15%. This reflects a broader trend in vaccine development to address age-related disparities.

Q: Could this vaccine be used alongside existing HIV prevention methods?

A: Absolutely. Public health experts emphasize that an HIV vaccine would complement—not replace—existing prevention tools like pre-exposure prophylaxis (PrEP), condoms, and regular testing. The goal is a layered approach, where vaccines reduce the overall burden of new infections while other methods fill gaps in protection.

Q: Are there other vaccines in development that might succeed where this one fell short?

A: Yes. Several other approaches are in various stages of testing, including:

• A broadly neutralizing antibody (bNAb) cocktail developed by the International AIDS Vaccine Initiative (IAVI), which has shown promise in early trials.
• A viral vector-based vaccine (using adenoviruses to deliver HIV genes) being tested by Janssen Pharmaceuticals.
• A mucosal vaccine designed to trigger immune responses at the site of HIV entry (e.g., the gut or genital tract), currently in preclinical testing at the Scripps Research Institute.

Each has its own strengths and challenges, but the field is more diverse than ever.

—

The UNC-led study is a reminder that scientific progress is rarely linear. The setback for older adults offers a roadmap forward—one that demands creativity, persistence, and a willingness to rethink long-held assumptions. For now, the HIV vaccine remains a work in progress, but the fact that researchers are even asking these questions is a sign of how far the field has come.

What’s clear is that the next chapter in HIV vaccine research will need to write older adults into the story—not as an afterthought, but as a central focus. And that may just be the breakthrough the field has been waiting for.